ClinicalTrials.gg
CompletedNCT05827978IGNITE P303Updated Jul 10, 2025Results posted

Study of mRNA-1010 Seasonal Influenza Vaccine in Adults

A Phase 3 interventional study of mRNA-1010 and Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine in Seasonal Influenza, sponsored by ModernaTX, Inc.. Completed at 103 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-10.

Primary conditionInfluenza, HumanRegistry: Virus DiseasesReclassifiedWhy we changed it
Registry
Virus Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Influenza, Human
Why
  1. The study's listed conditions name Influenza, Human, a narrower term within Virus Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8,411
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.

Enrollment
3rd of 12
8,411 · median 471
Started
2023
with 1 other
Phase 3
4 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
12 of 12
ModernaTX, Inc.

Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 3rd largest by enrollment, is one of 2 that started in 2023, is one of 4 in phase 3, and was the 8th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About mRNA-1010 influenza vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, or all of them as a file.
02

Study summary

This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.

03

Conditions studied

  • Seasonal Influenza

Browse trials for

Keywords

  • mRNA-1010
  • Virus Diseases
  • Flu
  • Influenza vaccine
  • Moderna
  • mRNA vaccine
04

In context

Influenza, Human Reclassified

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

This study's enrollment of 8,411 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.

Browse Influenza, Human studies →

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Compared within Influenza, Human, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Virus Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Investigator has assessed that the participant understands and is willing and physically able to comply with protocol mandated follow up, including all procedures.
  • For assigned females at birth and of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, and agreement to continue adequate contraception through 90 days following vaccine administration.

Part A:

  • At least 18 years of age inclusive, at the time of signing the form (ICF).

Part B:

  • At least 18 and \<65 years of age, at the time of signing the ICF.

Part C:

  • At least 65 years of age or older, at the time of signing the ICF.

Exclusion criteria

Exclusion Criteria:

  • Participant has had close contact with someone with laboratory-confirmed influenza infection or with someone who has been treated with antiviral therapies for influenza (for example, Tamiflu®) within the past 5 days prior to Day 1.
  • Participant is acutely ill or febrile (temperature ≥38.0℃elcius [100.4°Fahrenheit]) 72 hours prior to or at the Screening visit or Day 1. Participants meeting this criterion may be rescheduled within the 28-day screening window.
  • Participant has a history of a diagnosis or condition that, in the judgment of the investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.
  • Reported history of congenital or acquired immunodeficiency, condition or immune-mediated disease, asplenia, or recurrent severe infections.
  • Participant has tested positive for influenza by local health authority-approved testing methods within 150 days (for Part A) or 180 days (for Parts B and C) prior to Day 1.
  • Reported history of anaphylaxis or severe reaction after receipt of mRNA vaccines or any components of the mRNA-1010 or influenza vaccines, including egg protein.
  • Participant has received systemic immunosuppressants for >14 days in total within 180 days prior to Day 1 (for , ≥10 mg/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study. Inhaled, nasal and topical steroids are allowed. Intra-articular and epidural steroid injections are not allowed within 28 days before and/or after study intervention dosing.
  • Participant has received any vaccine authorized or approved by local health agency ≤28 days prior to study intervention dosing (Day 1) or plans to receive a vaccine authorized or approved by local health agency within 28 days before or after study intervention dosing.
  • Participant has received a licensed seasonal influenza vaccine within 5 months (150 days) (for part A) or within 6 months (180 days) (for Parts B and C) prior to Day 1.
  • Participant has participated in any seasonal influenza vaccine study within12 months prior to Day 1.
  • Participant is not aware whether they have received an influenza vaccine in the most recent influenza season (in the prior 12 months) (for Part A) or since September 2022 (for Parts B and C).
  • Participant has donated ≥450 milliliters (mL) of blood products within 28 days prior to Day 1 or plans to donate blood products during the study.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
8,411 participants (actual)

Study arms

  • Experimental
    mRNA-1010

    Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.

    Biological: mRNA-1010

  • Active comparator
    Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine

    Participants will receive a single dose of licensed quadrivalent inactivated seasonal influenza vaccine by IM injection on Day 1.

    Biological: Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine

Interventions

  • BiologicalmRNA-1010

    Sterile liquid for injection

    Also known as: Seasonal influenza vaccine

  • BiologicalLicensed Quadrivalent Inactivated Seasonal Influenza Vaccine

    Sterile suspension for injection

    Also known as: Fluarix Quadrivalent, Fluzone HD

07

What researchers measure

Primary outcomes

  1. Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody Levels as Measured by Hemagglutination Inhibition (HAI)

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains. Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were converted to the ULOQ.

    Time frame: Day 29

  2. Percentage of Participants Reaching Seroconversion, as Measured by HAI

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains. Seroconversion rate was defined as the percentage of participants with either a Baseline HAI titer \<1:10 and a postbaseline titer ≥1:40 or a Baseline HAI titer ≥1:10 and a minimum 4-fold rise in postbaseline HAI antibody titer. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were converted to the ULOQ.

    Time frame: Day 29

  3. Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

    Solicited ARs, representative of vaccine reactogenicity, were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Per prespecified analysis, only solicited ARs that were assessed and confirmed by the Investigator as both serious and related to IP were recorded as an adverse event. These adverse events were recorded as a serious AE (SAE) and are included in the summary of SAEs in the "Reported Adverse Events" section.

    Time frame: Up to 7 days after study injection

  4. Number of Participants With Unsolicited Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Unsolicited AEs included any AE not collected as a solicited AR, and also included solicited ARs assessed and confirmed as both serious and related by the Investigator. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Up to 28 days after study injection

  5. Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), SAEs, and AEs Leading to Discontinuation

    An MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Day 1 through Day 181

Secondary outcomes

  1. Percentage of Participants With HAI Titer ≥1:40

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains.

    Time frame: Day 29

  2. Geometric Mean Fold-Rise (GMFR) of Postinjection Anti-HA Antibodies for Influenza, as Measured by HAI Assay

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains. The GMFR measured the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% confidence interval (CI) for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

    Time frame: Baseline (Day 1) to Day 29

Other outcomes

  1. Number of Deaths Related to Study Drug

    A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

    Time frame: Day 1 through Day 181

08

Results

Posted Jul 10, 2025

Participant flow

Participant flow — Overall Study
MilestonePart A: Fluarix Quadrivalent Influenza Vaccine (QIV)Part A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone High Dose (HD) QIVPart C: mRNA-1010
Started118912251494150014961507
Safety set118012201488149214901502
Completed110611131425143414561484
Not completed8311269664023
Withdrew: Adverse event100100
Withdrew: Death152313
Withdrew: Lost to follow-up578854472510
Withdrew: Noncompliance with study procedures011110
Withdrew: Physician decision201211
Withdrew: Protocol violation520000
Withdrew: Withdrawal by subject17161012109
Withdrew: Other than specified001020

Outcome measures

PrimaryGeometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody Levels as Measured by Hemagglutination Inhibition (HAI)

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains. Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were converted to the ULOQ.

Time frame:
Day 29
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody Levels as Measured by Hemagglutination Inhibition (HAI)
titerPart A: Fluarix QIVPart A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone HD QIVPart C: mRNA-1010
Influenza A H1N1 Antibody147.49 (138.07 to 157.55)220.17 (207.30 to 233.84)137.90 (129.89 to 146.40)208.10 (196.43 to 220.47)130.09 (122.86 to 137.74)174.81 (165.15 to 185.04)
Influenza A H3N2 Antibody107.21 (101.11 to 113.68)152.56 (144.13 to 161.48)97.18 (91.74 to 102.95)157.88 (148.45 to 167.91)116.24 (109.47 to 123.44)141.62 (133.29 to 150.46)
Influenza B/Victoria Antibody155.94 (147.78 to 164.55)198.55 (188.44 to 209.22)150.90 (144.37 to 157.73)196.71 (187.68 to 206.17)195.97 (187.44 to 204.89)248.03 (237.34 to 259.21)
Influenza B/Yamagata Antibody146.63 (138.91 to 154.78)182.94 (173.61 to 192.76)113.76 (109.21 to 118.51)158.58 (151.55 to 165.93)91.94 (88.33 to 95.71)104.82 (100.70 to 109.11)
PrimaryPercentage of Participants Reaching Seroconversion, as Measured by HAI

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains. Seroconversion rate was defined as the percentage of participants with either a Baseline HAI titer \<1:10 and a postbaseline titer ≥1:40 or a Baseline HAI titer ≥1:10 and a minimum 4-fold rise in postbaseline HAI antibody titer. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were converted to the ULOQ.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Seroconversion, as Measured by HAI
percentage of participantsPart A: Fluarix QIVPart A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone HD QIVPart C: mRNA-1010
Influenza A H1N1 Antibody34.9 (32.12 to 37.74)50.2 (47.32 to 53.10)45.0 (42.42 to 47.65)64.4 (61.87 to 66.88)36.3 (33.75 to 38.84)49.7 (47.06 to 52.31)
Influenza A H3N2 Antibody32.2 (29.45 to 34.96)51.1 (48.17 to 53.94)44.0 (41.37 to 46.59)66.4 (63.91 to 68.85)47.8 (45.20 to 50.48)56.4 (53.80 to 59.02)
Influenza B/Victoria Antibody17.0 (14.86 to 19.32)26.6 (24.09 to 29.20)18.4 (16.39 to 20.48)33.0 (30.54 to 35.46)20.2 (18.09 to 22.35)29.8 (27.46 to 32.27)
Influenza B/Yamagata Antibody24.7 (22.19 to 27.29)33.2 (30.57 to 36.01)23.4 (21.25 to 25.71)35.6 (33.12 to 38.13)20.2 (18.09 to 22.35)26.0 (23.77 to 28.40)
PrimaryNumber of Participants With Solicited Local and Systemic Adverse Reactions (ARs)

Solicited ARs, representative of vaccine reactogenicity, were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Per prespecified analysis, only solicited ARs that were assessed and confirmed by the Investigator as both serious and related to IP were recorded as an adverse event. These adverse events were recorded as a serious AE (SAE) and are included in the summary of SAEs in the "Reported Adverse Events" section.

Time frame:
Up to 7 days after study injection
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
ParticipantsPart A: Fluarix QIVPart A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone HD QIVPart C: mRNA-1010
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)682106079611587341131
PrimaryNumber of Participants With Unsolicited Adverse Events (AEs)

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Unsolicited AEs included any AE not collected as a solicited AR, and also included solicited ARs assessed and confirmed as both serious and related by the Investigator. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Up to 28 days after study injection
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events (AEs)
ParticipantsPart A: Fluarix QIVPart A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone HD QIVPart C: mRNA-1010
Number of Participants With Unsolicited Adverse Events (AEs)134145134147137155
PrimaryNumber of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), SAEs, and AEs Leading to Discontinuation

An MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Day 1 through Day 181
Reported as:
Count of participants · Participants
Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), SAEs, and AEs Leading to Discontinuation
ParticipantsPart A: Fluarix QIVPart A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone HD QIVPart C: mRNA-1010
MAAEs195226223217248257
AESIs210112
SAEs212722253841
AEs Leading to Discontinuation100100
SecondaryPercentage of Participants With HAI Titer ≥1:40

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Percentage of Participants With HAI Titer ≥1:40
percentage of participantsPart A: Fluarix QIVPart A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone HD QIVPart C: mRNA-1010
Influenza A H1N1 Antibody93.7 (92.17 to 95.08)96.7 (95.53 to 97.65)92.0 (90.47 to 93.36)96.4 (95.29 to 97.29)92.3 (90.82 to 93.67)96.5 (95.40 to 97.38)
Influenza A H3N2 Antibody92.0 (90.25 to 93.50)97.0 (95.92 to 97.93)86.4 (84.51 to 88.13)92.6 (91.17 to 93.94)88.9 (87.10 to 90.45)92.8 (91.38 to 94.13)
Influenza B/Victoria Antibody99.3 (98.62 to 99.70)99.7 (99.14 to 99.91)99.4 (98.90 to 99.76)99.4 (98.82 to 99.71)99.5 (98.98 to 99.80)100 (99.74 to 100.00)
Influenza B/Yamagata Antibody97.5 (96.45 to 98.35)98.5 (97.61 to 99.10)97.4 (96.44 to 98.17)97.8 (96.88 to 98.48)93.7 (92.28 to 94.90)96.1 (95.01 to 97.08)
SecondaryGeometric Mean Fold-Rise (GMFR) of Postinjection Anti-HA Antibodies for Influenza, as Measured by HAI Assay

Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains. The GMFR measured the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% confidence interval (CI) for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

Time frame:
Baseline (Day 1) to Day 29
Reported as:
Geometric mean · ratio
Geometric Mean Fold-Rise (GMFR) of Postinjection Anti-HA Antibodies for Influenza, as Measured by HAI Assay
ratioPart A: Fluarix QIVPart A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone HD QIVPart C: mRNA-1010
Influenza A H1N1 Antibody2.78 (2.59 to 2.99)4.03 (3.80 to 4.27)3.29 (3.10 to 3.49)4.99 (4.73 to 5.26)2.60 (2.47 to 2.74)3.49 (3.32 to 3.67)
Influenza A H3N2 Antibody2.60 (2.46 to 2.76)3.68 (3.49 to 3.87)3.16 (2.99 to 3.35)5.33 (5.04 to 5.64)3.40 (3.22 to 3.60)4.12 (3.90 to 4.36)
Influenza B/Victoria Antibody1.75 (1.67 to 1.84)2.22 (2.12 to 2.32)1.85 (1.78 to 1.93)2.47 (2.37 to 2.57)1.89 (1.82 to 1.97)2.35 (2.26 to 2.45)
Influenza B/Yamagata Antibody2.10 (1.99 to 2.22)2.63 (2.52 to 2.76)2.01 (1.93 to 2.10)2.79 (2.67 to 2.91)1.92 (1.85 to 2.00)2.20 (2.13 to 2.28)
Other pre-specifiedNumber of Deaths Related to Study Drug

A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

Time frame:
Day 1 through Day 181
Reported as:
Count of participants · Participants
Number of Deaths Related to Study Drug
ParticipantsPart A: Fluarix QIVPart A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone HD QIVPart C: mRNA-1010
Number of deaths152313
Number of deaths assessed by Sponsor as related to study drug000000
Number of deaths assessed by Investigator as related to study drug010000

Adverse events

Collected over All-cause mortality and serious adverse events were collected from Day 1 through Day 181. Other (not including serious) unsolicited adverse events were collected up to 28 days after study injection (that is, Day 1 up to Day 29). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Fluarix QIV1/1,189 (0.1%)21/1,180 (1.8%)0/1,180 (0%)
Part A: mRNA-10105/1,225 (0.4%)27/1,220 (2.2%)0/1,220 (0%)
Part B: Fluarix QIV2/1,494 (0.1%)22/1,488 (1.5%)0/1,488 (0%)
Part B: mRNA-10103/1,500 (0.2%)25/1,492 (1.7%)0/1,492 (0%)
Part C: Fluzone HD QIV1/1,496 (0.1%)38/1,490 (2.6%)0/1,490 (0%)
Part C: mRNA-10103/1,507 (0.2%)41/1,502 (2.7%)0/1,502 (0%)
Most frequent serious events
Showing 10 of 149
Most frequent serious events
EventPart A: Fluarix QIVPart A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone HD QIVPart C: mRNA-1010
PneumoniaInfections and infestations3/11801/12201/14882/14921/14903/1502
CellulitisInfections and infestations0/11802/12201/14881/14920/14901/1502
Deep vein thrombosisVascular disorders0/11802/12200/14880/14920/14901/1502
DeathGeneral disorders0/11802/12201/14880/14920/14901/1502
Acute myocardial infarctionCardiac disorders0/11801/12202/14880/14921/14902/1502
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/11801/12202/14880/14921/14902/1502
NephrolithiasisRenal and urinary disorders0/11800/12200/14880/14922/14900/1502
FallInjury, poisoning and procedural complications0/11801/12200/14880/14922/14900/1502
Hip fractureInjury, poisoning and procedural complications0/11801/12200/14880/14922/14901/1502
Subdural haematomaInjury, poisoning and procedural complications0/11800/12200/14880/14922/14900/1502

Baseline characteristics

Randomization set included all participants who were randomly assigned to the study intervention, regardless of the participants' study intervention status in the study. Participants were analyzed according to the group to which they were randomized.

Age, Categorical
Age, Categorical(Participants)Part A: Fluarix QIVPart A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone HD QIVPart C: mRNA-1010Total
<=18 years0000000
Between 18 and 65 years91995114941500104865
>=65 years27027400149515073546
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Fluarix QIVPart A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone HD QIVPart C: mRNA-1010Total
Female6276639068828558834816
Male5625625886186416243595
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Fluarix QIVPart A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone HD QIVPart C: mRNA-1010Total
Hispanic or Latino2262623924064564512193
Not Hispanic or Latino94894110831076102510416114
Unknown or Not Reported152219181515104
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Fluarix QIVPart A: mRNA-1010Part B: Fluarix QIVPart B: mRNA-1010Part C: Fluzone HD QIVPart C: mRNA-1010Total
Race — White8569229701020122412576249
Race — Black or African American2742504464202372271854
Race — Asian342728241010133
Race — American Indian or Alaska Native5712129449
Race — Native Hawaiian or Other Pacific Islander13440214
Race — Multiple11111866254
Race — Other337114129
Race — Not Reported30622316
Race — Unknown22314113
09

Study locations

103 sites
  • Pinnacle Research Group
    Anniston, Alabama 36207, United States
  • North Alabama Research Center LLC
    Athens, Alabama 35611, United States
  • Cullman Research Center
    Cullman, Alabama 35055, United States
  • Medical Affiliated Research Center Inc
    Huntsville, Alabama 35801-6002, United States
  • Desert Clinical Research - CCT
    Mesa, Arizona 85213, United States
  • Foothills Research Center - CCT
    Phoenix, Arizona 85044, United States
  • Fiel Family &amp; Sports Medicine - PC - CCT
    Tempe, Arizona 85283, United States
  • Noble Clinical Research
    Tucson, Arizona 85704, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • Velocity Clinical Research, Banning
    Banning, California 92220, United States
  • Synexus Clinical Research US, Inc. - Cerritos
    Cerritos, California 90703, United States
  • Marvel Clinical Research 002, LLC
    Huntington Beach, California 92647, United States
  • Velocity Clinical Research
    La Mesa, California 91942, United States
  • Pasadena Clinical Trials
    Pasadena, California 91105, United States
  • Artemis Institute For Clinical Research LLC - Riverside - Headlands
    Riverside, California 92503, United States
  • Peninsula Research Associates - CRN
    Rolling Hills Estates, California 90274, United States
  • Optimal Research, LLC
    San Diego, California 92108, United States
  • Acclaim Clinical Research
    San Diego, California 92120, United States
  • Optimus Medical Group
    San Francisco, California 94102, United States
  • Chase Medical Research LLC - Waterbury
    Waterbury, Connecticut 06708, United States
  • Velocity Clinical Research - Hallandale Beach
    Hallandale, Florida 33009, United States
  • Indago Research and Health Center
    Hialeah, Florida 33012, United States
  • NeoClinical Reseaarch
    Hialeah, Florida 33016, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Health Awareness Inc
    Jupiter, Florida 33458, United States
  • Wr-Msra, Llc.
    Lake City, Florida 32055, United States
  • Sandhill Research, LLC d/b/a Accel Research Sites Network
    Lake Mary, Florida 32746, United States
  • Sandhill Research, LLC d/b/a Accel Research Sites
    Lake Mary, Florida 32746, United States
  • University Clinical Research-DeLand, LLC d/b/a Accel Research
    Lake Mary, Florida 32746, United States
  • South Florida Research Center, Inc
    Miami, Florida 33135, United States
  • Miami Clinical Research
    Miami, Florida 33155, United States
  • Suncoast Research Associates, LLC
    Miami, Florida 33173, United States
  • Clinical Site Partners, LLC dba Flourish Research
    Miami, Florida 33186, United States
  • Floridian Clinical Research
    Miami Lakes, Florida 33016, United States
  • Innovation Medical Group, LLC.
    Palmetto Bay, Florida 33157, United States
  • Suncoast Research Associates, LLC
    Pembroke Pines, Florida 33024, United States
  • St. Johns Center for Clinical Research - ERN
    Saint Augustine, Florida 32086, United States
  • New Tampa Health, Inc.
    Tampa, Florida 33603, United States
  • Synexus Clinical Research US, Inc. - The Villages
    The Villages, Florida 32162, United States
  • Synexus Clinical Research US, Inc. - Atlanta
    Atlanta, Georgia 30328, United States
  • CenExel iResearch, LLC
    Decatur, Georgia 30030, United States
  • Javara, Inc.
    Fayetteville, Georgia 30214, United States
  • Velocity Clinical Research, Savannah
    Savannah, Georgia 31406, United States
  • CRA, Headlands LLC
    Stockbridge, Georgia 30281, United States
  • Synexus Clinical Research US, Inc. - Chicago
    Chicago, Illinois 60602, United States
  • Great Lakes Clinical Trials- Ravenswood
    Chicago, Illinois 60640, United States
  • DM Clinical Research
    River Forest, Illinois 60305, United States
  • Velocity Clinical Research - Valparaiso
    Valparaiso, Indiana 46383, United States
  • Johnson County Clin-Trials (JCCT)
    Lenexa, Kansas 66219, United States
  • Alliance for Multispecialty Research, LLC
    Newton, Kansas 67114, United States
  • Velocity Clinical Research, Inc.
    Overland Park, Kansas 66210, United States
  • Alliance for Multispecialty Research, LLC
    Wichita, Kansas 67205, United States
  • Velocity Clinic Research, Inc.
    Baton Rouge, Louisiana 70809, United States
  • Velocity Clinical Research, Covington
    Covington, Louisiana 70433, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • Javara Inc.
    Annapolis, Maryland 21401, United States
  • Velocity Clinical Research, Rockville
    Rockville, Maryland 20854, United States
  • Oakland Medical Research
    Troy, Michigan 48085, United States
  • Clinical Research Institute, Inc - CRN
    Minneapolis, Minnesota 55402, United States
  • DelRicht Research
    Gulfport, Mississippi 39503, United States
  • Velocity Clinical Research, Gulfport
    Gulfport, Mississippi 39503, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO
    Springfield, Missouri 65802, United States
  • Sundance Clinical Research, LLC
    St Louis, Missouri 63141, United States
  • Methodist Physicians Clinic - CCT Research
    Fremont, Nebraska 68025, United States
  • Velocity Clinical Research- Grand Island
    Grand Island, Nebraska 68803, United States
  • Velocity Clinical Research (Norfolk - Nebraska) - PPDS
    Norfolk, Nebraska 68701, United States
  • Velocity Clinical Research (Omaha - Nebraska) - PPDS
    Omaha, Nebraska 68134, United States
  • Velocity Clinical Research, Inc.
    Omaha, Nebraska 68134, United States
  • Midwest Regional Health Services - LLC - CCT
    Omaha, Nebraska 68144, United States
  • Alliance for Multispecialty Research, LLC
    Las Vegas, Nevada 89119, United States
  • Velocity Clinical Research (Binghamton - New York) - PPDS
    Binghamton, New York 13905, United States
  • Velocity Clinical Research, Syracuse
    East Syracuse, New York 13057, United States
  • Rochester Clinical Research, Inc
    Rochester, New York 14609, United States
  • Velocity Clinical Research, Inc.
    Vestal, New York 13850, United States
  • Javara Inc.
    Charlotte, North Carolina 28210, United States
  • Lucas Research Inc.
    Morehead City, North Carolina 28557, United States
  • M3 Wake Research, Inc
    Raleigh, North Carolina 27612, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Velocity Clinical Research, Mt. Auburn
    Cincinnati, Ohio 45219, United States
  • Velocity Clinical Research, Inc.
    Cincinnati, Ohio 45246, United States
  • DelRicht Research
    Tulsa, Oklahoma 74133, United States
  • Velocity Clinical Research - Grants Pass
    Grants Pass, Oregon 97527, United States
  • DM Clinical Research - Philadelphia - ERN
    Philadelphia, Pennsylvania 19107, United States
  • Velocity Clinical Research - Columbia
    Columbia, South Carolina 29204, United States
  • Velocity Clinical Research - Gaffney
    Gaffney, South Carolina 29340, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • DelRicht Research
    Hendersonville, Tennessee 37075, United States
  • Tekton Research - Austin - PPDS
    Austin, Texas 78745, United States
  • Tekton Research, LLC.
    Beaumont, Texas 77706, United States
  • Javara Inc.
    Conroe, Texas 77384, United States
  • Epic Medical Research - DeSoto
    DeSoto, Texas 75115, United States
  • DM Clinical Research
    Houston, Texas 77065, United States
  • DM Clinical Research
    Humble, Texas 77338, United States
  • Epic Clinical Research
    Lewisville, Texas 75057, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • DM Clinical Research
    Sugar Land, Texas 77478, United States
  • Javara Inc.
    Sugar Land, Texas 77478, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Cope Family Medicine - CCT
    Bountiful, Utah 84010, United States
  • J. Lewis Research, Inc., Foothill Family Clinic
    Salt Lake City, Utah 84109, United States

Showing the first 100 of 103 sites. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Soens M, Ananworanich J, Hicks B, Lucas KJ, Cardona J, Sher L, Livermore G, Schaefers K, Henry C, Choi A, Avanesov A, Chen R, Du E, Pucci A, Das R, Miller J, Nachbagauer R. A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults. Vaccine. 2025 Mar 19;50:126847. doi: 10.1016/j.vaccine.2025.126847. Epub 2025 Feb 7. PubMed 39919447 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jun 2024, 14 months.

Results were first posted in Jul 2025, 1 year after primary completion.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 14 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2023
First posted
Apr 25, 2023
StartActual
Apr 17, 2023
Primary completionActual
Jun 24, 2024
CompletionActual
Jun 24, 2024
Results first posted
Jul 10, 2025
Last update
Jul 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05827978
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Apr 25, 2023
Start date
Apr 17, 2023
Primary completion
Jun 24, 2024
Completion
Jun 24, 2024
Results posted
Jul 10, 2025
Last update
Jul 10, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1010 influenza vaccine

Start the discussion